These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2683021)

  • 1. Pathogenicity of Campylobacter pylori--a causative factor in gastritis?
    McNulty CA
    Scand J Gastroenterol Suppl; 1989; 160():3-6. PubMed ID: 2683021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori.
    McNulty CA
    Rev Infect Dis; 1990; 12 Suppl 1():S94-8. PubMed ID: 2406863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Campylobacter pylori does not alter gastric acid secretion.
    Montbriand JR; Appelman HD; Cotner EK; Nostrant TT; Elta GH
    Am J Gastroenterol; 1989 Dec; 84(12):1513-6. PubMed ID: 2596452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bismuth subsalicylate treatment in chronic Campylobacter pylori-associated erosive gastritis].
    Malfertheiner P; Stanescu A; Baczako K; Vanek E; Bode G; Ditschuneit H
    Dtsch Med Wochenschr; 1988 Jun; 113(23):923-9. PubMed ID: 3378501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin.
    Drumm B; Sherman P; Chiasson D; Karmali M; Cutz E
    J Pediatr; 1988 Nov; 113(5):908-12. PubMed ID: 3183851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campylobacter pylori--therapy review.
    Axon AT
    Scand J Gastroenterol Suppl; 1989; 160():35-8. PubMed ID: 2683022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.
    McNulty CA; Gearty JC; Crump B; Davis M; Donovan IA; Melikian V; Lister DM; Wise R
    Br Med J (Clin Res Ed); 1986 Sep; 293(6548):645-9. PubMed ID: 3092967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ulcer symptoms without demonstration of ulcer: causative therapy with demonstration of Helicobacter pylori].
    Kobler E; Müller B; Wüst W
    Schweiz Rundsch Med Prax; 1990 Mar; 79(13):398-9. PubMed ID: 2320815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate.
    Loffeld RJ; Potters HV; Stobberingh E; Flendrig JA; van Spreeuwel JP; Arends JW
    Gut; 1989 Sep; 30(9):1206-12. PubMed ID: 2680795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Campylobacter pylori infection in uremic dialyzed patients. Eradication of the infection by colloidal bismuth subcitrate.
    Conz P; Feriani M; Milan M; Bernardini D; Crepaldi C; La Greca G
    Nephron; 1990; 55(4):442-3. PubMed ID: 2392203
    [No Abstract]   [Full Text] [Related]  

  • 12. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.
    Rauws EA; Langenberg W; Houthoff HJ; Zanen HC; Tytgat GN
    Gastroenterology; 1988 Jan; 94(1):33-40. PubMed ID: 3335295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of bismuth subsalicylate on the histologic gastritis seen with Campylobacter pylori: a placebo-controlled, randomized study.
    Lanza FL; Skoglund ML; Rack MF; Yardley JH
    Am J Gastroenterol; 1989 Sep; 84(9):1060-4. PubMed ID: 2773899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dose-effect studies with bismuth salts for the elimination of Campylobacter pylori].
    Menge H; Hofmann J; Gregor M
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():44-6. PubMed ID: 3318192
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).
    Morris A; Brown P; Ali MR; Lane M; Palmer R
    N Z Med J; 1988 Oct; 101(856 Pt 1):651-4. PubMed ID: 3054641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori infection and chronic gastritis: clinical, serological, and histologic correlations in children treated with amoxicillin and colloidal bismuth subcitrate.
    De Giacomo C; Fiocca R; Villani L; Lisato L; Licardi G; Diegoli N; Donadini A; Maggiore G
    J Pediatr Gastroenterol Nutr; 1990 Oct; 11(3):310-6. PubMed ID: 2246711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
    Humphreys H; Bourke S; Dooley C; McKenna D; Power B; Keane CT; Sweeney EC; O'Moráin C
    Gut; 1988 Mar; 29(3):279-83. PubMed ID: 3356357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with Campylobacter pylori in western Kentucky.
    Kraus JW; Morello PJ
    J Ky Med Assoc; 1989 Sep; 87(9):448-50. PubMed ID: 2794757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperplastic gastric polyps associated with persistent Helicobacter pylori infection and active gastritis.
    Veereman Wauters G; Ferrell L; Ostroff JW; Heyman MB
    Am J Gastroenterol; 1990 Oct; 85(10):1395-7. PubMed ID: 2220735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.